The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation.

Détails

Ressource 1Télécharger: document.pdf (1803.04 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_A62033B5071E
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation.
Périodique
Cardiovascular Diabetology
Auteur(s)
Fruchart J.C., Santos R.D., Aguilar-Salinas C., Aikawa M., Al Rasadi K., Amarenco P., Barter P.J., Ceska R., Corsini A., Després J.P., Duriez P., Eckel R.H., Ezhov M.V., Farnier M., Ginsberg H.N., Hermans M.P., Ishibashi S., Karpe F., Kodama T., Koenig W., Krempf M., Lim S., Lorenzatti A.J., McPherson R., Nuñez-Cortes J.M., Nordestgaard B.G., Ogawa H., Packard C.J., Plutzky J., Ponte-Negretti C.I., Pradhan A., Ray K.K., Reiner Ž., Ridker P.M., Ruscica M., Sadikot S., Shimano H., Sritara P., Stock J.K., Su T.C., Susekov A.V., Tartar A., Taskinen M.R., Tenenbaum A., Tokgözoğlu L.S., Tomlinson B., Tybjærg-Hansen A., Valensi P., Vrablík M., Wahli W., Watts G.F., Yamashita S., Yokote K., Zambon A., Libby P.
ISSN
1475-2840 (Electronic)
ISSN-L
1475-2840
Statut éditorial
Publié
Date de publication
04/06/2019
Peer-reviewed
Oui
Volume
18
Numéro
1
Pages
71
Langue
anglais
Résumé
In the era of precision medicine, treatments that target specific modifiable characteristics of high-risk patients have the potential to lower further the residual risk of atherosclerotic cardiovascular events. Correction of atherogenic dyslipidemia, however, remains a major unmet clinical need. Elevated plasma triglycerides, with or without low levels of high-density lipoprotein cholesterol (HDL-C), offer a key modifiable component of this common dyslipidemia, especially in insulin resistant conditions such as type 2 diabetes mellitus. The development of selective peroxisome proliferator-activated receptor alpha modulators (SPPARMα) offers an approach to address this treatment gap. This Joint Consensus Panel appraised evidence for the first SPPARMα agonist and concluded that this agent represents a novel therapeutic class, distinct from fibrates, based on pharmacological activity, and, importantly, a safe hepatic and renal profile. The ongoing PROMINENT cardiovascular outcomes trial is testing in 10,000 patients with type 2 diabetes mellitus, elevated triglycerides, and low levels of HDL-C whether treatment with this SPPARMα agonist safely reduces residual cardiovascular risk.
Mots-clé
Atherogenic dyslipidemia, Diabetes, Inflammation, PROMINENT, Pemafibrate (K-877), Remnant cholesterol, Residual cardiovascular risk, SPPARMalpha, Selective peroxisome proliferator-activated receptor alpha modulator, Triglycerides, Visceral obesity
Pubmed
Web of science
Open Access
Oui
Création de la notice
20/06/2019 9:53
Dernière modification de la notice
20/08/2019 16:11
Données d'usage